NASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis $1.04 -0.01 (-0.48%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$1.07 +0.03 (+2.79%) As of 11/16/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ProKidney Stock (NASDAQ:PROK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProKidney alerts:Sign Up Key Stats Today's Range$1.01▼$1.1050-Day Range$1.04▼$1.9952-Week Range$0.87▼$2.65Volume1.71 million shsAverage Volume1.41 million shsMarket Capitalization$314.41 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment. ProKidney is based in Winston-Salem, North Carolina. Its activities are centered on research and clinical development of REACT and related cell therapy approaches.AI Generated. May Contain Errors. Read More ProKidney Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScorePROK MarketRank™: 1.828293592645 of 5 starsProKidney scored higher than 37% of companies evaluated by MarketBeat, and ranked 717th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialProKidney has a consensus price target of $10.00, representing about 861.5% upside from its current price of $1.04.Amount of Analyst CoverageProKidney has only been the subject of 2 research reports in the past 90 days.Read more about ProKidney's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ProKidney are expected to decrease in the coming year, from ($0.51) to ($0.75) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.38% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 22.51, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently decreased by 0.94%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.24 News SentimentProKidney has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for ProKidney this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,067,315.00 in company stock.Percentage Held by Insiders39.83% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProKidney's insider trading history. Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PROK Stock News HeadlinesFY2030 EPS Estimate for ProKidney Decreased by AnalystNovember 16 at 2:13 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: ProKidney (PROK) and Arrowhead Pharmaceuticals (ARWR)November 15 at 9:36 AM | theglobeandmail.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders. | Base Camp Trading (Ad)H.C. Wainwright Remains a Buy on ProKidney (PROK)November 15 at 9:36 AM | theglobeandmail.comProKidney Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMProKidney Q3 2026: Wider Loss Signals a High-Stakes Trial SprintNovember 12, 2026 | 247wallst.comProKidney Reports Third Quarter 2026 Financial Results and Business HighlightsNovember 12, 2026 | globenewswire.comProKidney (PROK) Expected to Post Quarterly Earnings on MondayNovember 8, 2026 | americanbankingnews.comSee More Headlines PROK Stock Analysis - Frequently Asked Questions How have PROK shares performed this year? ProKidney's stock was trading at $2.24 on January 1st, 2026. Since then, PROK stock has decreased by 53.6% and is now trading at $1.04. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) released its earnings results on Thursday, November, 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The firm had revenue of $174 thousand for the quarter, compared to analysts' expectations of $125 thousand. Who are ProKidney's major shareholders? ProKidney's top institutional investors include State Street Corp (0.60%), Simplify Asset Management Inc., Abel Hall LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Control Empresarial De Capital, Pablo G Legorreta, Brian Jg Pereira and Darin J Weber. View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProKidney own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Tesla (TSLA), D-Wave Quantum (QBTS), Rumble (RUM), Super Micro Computer (SMCI), NuScale Power (SMR) and Alight (ALIT). Company Calendar Last Earnings11/12/2026Today11/17/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PROK's financial health is in the Yellow zone, according to TradeSmith. PROK has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PROK CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees231Year FoundedN/APrice Target and Rating Average Price Target for ProKidney$10.00 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+861.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.99 million Net Margins-13,326.71% Pretax Margin-20,388.38% Return on EquityN/A Return on Assets-35.31% Debt Debt-to-Equity RatioN/A Current Ratio8.36 Quick Ratio8.36 Sales & Book Value Annual Sales$890 thousand Price / Sales353.27 Cash FlowN/A Price / Cash FlowN/A Book Value($3.36) per share Price / Book-0.31Miscellaneous Outstanding Shares302,320,000Free Float181,908,000Market Cap$314.41 million OptionableOptionable Beta1.90 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:PROK) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.